Advanced Prostate Cancer VL

Cognitive Function and Hormone Therapy in Advanced Prostate Cancer - Interview with Alicia Morgans

(Length of Conversation: 7 min) Dr. Charles Ryan sits down with Dr. Alicia Morgans to discuss the study she's currently leading on Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer . This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. Spec...

Clinical Genomic Risk Classification - Daniel Spratt

A Conversation on Clinical Genomic Risk Classification - Alicia Morgans and Daniel Spratt (Length of Conversation: 25 min) Daniel Spratt, MD discusses the clinical challenges to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa) and how his team aimed to develop a novel clinical-genomic risk system that can...

PRONOUNCE Trial: Cardiovascular Outcomes in Prostate Cancer - Susan Slovin

(Length of Conversation: 19 min) Alicia Morgans, MD, MPH and Susan Slovin, MD, PhD, discuss the PRONOUNCE trial , which looks at cardiovascular outcomes in patients with prostate cancer. Dr. Slovin highlights the importance of considering cardiovascular disease as it is the second most common cause of death in men with prostate cancer. Literature in the past 15-20 years on the use a GNRH agonists...

Role of MRI in Men on Active Surveillance - Laurence Klotz

(Length of Discussion: 33 min) Tom Keane hosts a discussion with Laurence Klotz on the use of MRI in the detection of significant cancer and the possibility of MRI replacing biopsies in men on active surveillance. Dr. Klotz poses the question, can MRI replace biopsies in men on active surveillance? Through an overview of clinical trial data on 12 different published studies around this hot topic i...

Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? - Christopher Sweeney

(Length of discussion - 26 minutes) Christopher Sweeney, MD presents on the Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? Dr. Sweeney addresses how we can cure more men from prostate cancer by taking a look at preventing relapse after definitive local therapy and radiation and hormonal therapy together vs radiation therapy alone. He reflects on the length of ti...

Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

E. David Crawford hosts a discussion with Neal Shore and Jehonathan Pinthus on the adverse effects of androgen deprivation therapy (ADT). Viewers will gain knowledge on the optimal role of the antagonist vs agonist and a closer look at adverse effects of ADT and recommendations for patients undergoing ADT. The notion of sarcopenia and recommendations in fitness and strength training to reduce risk...

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?- Lorelei Mucci

(Length of lecture ~ 19 minutes) Alicia Morgans hosts a discussion with Lorelei Mucci on her recently-published article in the Journal of Clinical Oncology that reviews a study on the association between statin use and the mortality rate in Danish patients who have prostate cancer. This study leverages the unique data sets available in Scandinavian countries where nationwide health registers can b...

What the Referring Clinician Needs to Know from Molecular Imaging in Prostate Cancer - Felix Feng

(Length of lecture ~ 16 minutes) Dr. Feng provides a brief overview of prostate cancer management and how molecular imaging approaches can help guide the clinical management of prostate cancer, noting that imaging physicians need to educate their clinical colleagues about capabilities and limitations of these imaging studies. Additional content on molecular imaging ASCO 2017: How Advances in Molec...

Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing - Thomas Keane

(Length of video ~17 min) Thomas Keane discusses strategies to mitigate side effects of androgen deprivation therapy (ADT) and the difference between intermittent versus continuous ADT. Dr. Keane focuses his lecture on the side effect of hot flashes while undergoing ADT therapy and recommendations for the management of hot flashes. Also, discussed is bone health and the acceleration of bone loss i...

Plasma Based Biomarkers in Advanced Prostate Cancer - Gerhardt Attard

(Length of Presentation: 16 min) Gerhardt Attard, MD focuses on DNA Plasma-based biomarkers in advanced prostate cancer during his 2017 APCCC presentation on the rationale for using plasma DNA. Plasma collection is routine and are adding to the registries allows for ongoing clinical trials. Circulating tumor DNA is detected in plasma from all progressing mCRPC patients. Plasma DNA is representativ...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.